IT8223795A0 - Gamma), relativi veicoli di polipeptidi contenenti la sequenza espressione, loro procedimento di degli amminoacidi dell'interferone preparazione, composizioni umano immune (interferone umano farmaceutiche contenenti tali polipeptidi. - Google Patents

Gamma), relativi veicoli di polipeptidi contenenti la sequenza espressione, loro procedimento di degli amminoacidi dell'interferone preparazione, composizioni umano immune (interferone umano farmaceutiche contenenti tali polipeptidi.

Info

Publication number
IT8223795A0
IT8223795A0 IT8223795A IT2379582A IT8223795A0 IT 8223795 A0 IT8223795 A0 IT 8223795A0 IT 8223795 A IT8223795 A IT 8223795A IT 2379582 A IT2379582 A IT 2379582A IT 8223795 A0 IT8223795 A0 IT 8223795A0
Authority
IT
Italy
Prior art keywords
polypeptides
interferon
human
gamma
vehicles
Prior art date
Application number
IT8223795A
Other languages
English (en)
Other versions
IT1153265B (it
Inventor
David V Goeddel
Patrick W Gray
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211703&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT8223795(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IT8223795A0 publication Critical patent/IT8223795A0/it
Application granted granted Critical
Publication of IT1153265B publication Critical patent/IT1153265B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IT23795/82A 1981-10-19 1982-10-18 Polipeptidi contenenti la sequenza degli amminoacidi dell'interferone umano immune (interferone umano gamma), relativi veicoli di espressione, loro procedimento di preparazione, composizioni farmaceutiche contenenti tali polipeptidi IT1153265B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31248981A 1981-10-19 1981-10-19

Publications (2)

Publication Number Publication Date
IT8223795A0 true IT8223795A0 (it) 1982-10-18
IT1153265B IT1153265B (it) 1987-01-14

Family

ID=23211703

Family Applications (1)

Application Number Title Priority Date Filing Date
IT23795/82A IT1153265B (it) 1981-10-19 1982-10-18 Polipeptidi contenenti la sequenza degli amminoacidi dell'interferone umano immune (interferone umano gamma), relativi veicoli di espressione, loro procedimento di preparazione, composizioni farmaceutiche contenenti tali polipeptidi

Country Status (43)

Country Link
US (4) US4762791A (it)
EP (1) EP0077670B1 (it)
JP (3) JPS5890514A (it)
KR (1) KR840001837A (it)
AT (1) ATE44289T1 (it)
AU (1) AU561343B2 (it)
BG (2) BG44877A3 (it)
BR (1) BR8206068A (it)
CA (1) CA1341590C (it)
CH (1) CH663619A5 (it)
CZ (1) CZ282154B6 (it)
DD (1) DD208822A5 (it)
DE (4) DE77670T1 (it)
DK (1) DK163187C (it)
DZ (1) DZ467A1 (it)
ES (1) ES516620A0 (it)
FI (1) FI86559C (it)
FR (1) FR2514783B1 (it)
GB (1) GB2107718B (it)
GR (1) GR78391B (it)
GT (1) GT198277746A (it)
HK (1) HK66289A (it)
HU (1) HU202287B (it)
IE (1) IE54371B1 (it)
IL (1) IL66992A (it)
IT (1) IT1153265B (it)
LU (1) LU88327I2 (it)
MX (2) MX166499B (it)
MY (1) MY102546A (it)
NL (1) NL930040I2 (it)
NO (2) NO164177C (it)
NZ (1) NZ202190A (it)
OA (1) OA07233A (it)
PH (1) PH26963A (it)
PL (1) PL153202B1 (it)
PT (1) PT75696B (it)
RO (1) RO89534A (it)
RU (3) RU2056460C1 (it)
SG (1) SG76988G (it)
SK (1) SK279535B6 (it)
YU (1) YU45871B (it)
ZA (1) ZA827569B (it)
ZW (1) ZW22282A1 (it)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
JPS62223191A (ja) * 1981-12-24 1987-10-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチドの製法
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
GB8406910D0 (en) * 1984-03-16 1984-04-18 Biogen Nv Gamma interferon
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
ZA831094B (en) * 1982-02-22 1983-11-30 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US5827694A (en) * 1982-03-08 1998-10-27 Genentech, Inc. DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides
US6432677B1 (en) 1982-03-08 2002-08-13 Genentech, Inc. Non-human animal interferons
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPH0787797B2 (ja) * 1982-05-20 1995-09-27 サントリー株式会社 ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
AU571460B2 (en) * 1982-09-27 1988-04-21 Cancer Institute Of Japanese Foundation For Cancer Research Alpha interferon dna, recombinant plasmid, engineered organism and alpha interferon polypeptide
AU575301B2 (en) * 1982-10-08 1988-07-28 Juridical Foundation, Japanese Foundation For Cancer Research Novel vector
US5831023A (en) * 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
WO1984002129A1 (en) * 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GR79124B (it) * 1982-12-22 1984-10-02 Genentech Inc
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
JPH0740925B2 (ja) * 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
US7198919B1 (en) * 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
ZA843275B (en) * 1983-05-05 1984-12-24 Hoffmann La Roche Novel vectors for interferon expression
DK265384A (da) * 1983-06-01 1984-12-02 Hoffmann La Roche Polypeptider med interferonaktivitet
JP2551746B2 (ja) * 1983-07-19 1996-11-06 サントリー株式会社 改良プラスミドベクタ−およびその利用
DE3484374D1 (de) * 1983-08-04 1991-05-08 Green Cross Corp Gamma-interferonzusammensetzung.
JPS6034919A (ja) * 1983-08-04 1985-02-22 Green Cross Corp:The ガンマ・インタ−フェロン組成物
IL72773A0 (en) * 1983-08-29 1984-11-30 Meloy Lab Production of immune interferon and its mrna
US4476049A (en) * 1983-09-20 1984-10-09 Hoffmann-La Roche Inc. Method for the extraction of immune interferon
ZA846554B (en) * 1983-09-20 1985-04-24 Hoffmann La Roche Immune interferon and method for its purification
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US4604284A (en) * 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
JPS6079000A (ja) * 1983-10-04 1985-05-04 Takeda Chem Ind Ltd ヒトγ型インタ−フエロン単量体の製造法
JPH0788398B2 (ja) * 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
GB8328820D0 (en) * 1983-10-28 1983-11-30 Searle & Co Synthetic human gamma interferon gene
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
JPS60145098A (ja) * 1984-01-09 1985-07-31 Suntory Ltd 糖付加ポリペプチドの製造法
WO1985004420A1 (en) * 1984-03-29 1985-10-10 Takeda Chemical Industries, Ltd. Novel dna and its use
DE3414831A1 (de) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
GB8414354D0 (en) * 1984-06-05 1984-07-11 Biogen Nv Purifying protein
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
WO1985005618A1 (en) * 1984-06-06 1985-12-19 Takeda Chemical Industries, Ltd. Process for preparing interferon derivative
JPS60262594A (ja) * 1984-06-11 1985-12-25 Kanegafuchi Chem Ind Co Ltd ヒトインタ−フエロン−γ
CA1302320C (en) * 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
GB8414911D0 (en) * 1984-06-12 1984-07-18 Searle & Co Producing human gamma interferon
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
GB2164650A (en) * 1984-09-25 1986-03-26 Fujisawa Pharmaceutical Co Process for production of y-interferon
ATE66375T1 (de) * 1984-10-05 1991-09-15 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
DE3436638C2 (de) * 1984-10-05 1992-10-08 Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
JPS6188875A (ja) * 1984-10-05 1986-05-07 Kanegafuchi Chem Ind Co Ltd ヒトインタ−フエロン−γ
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
JPS61108397A (ja) * 1984-10-31 1986-05-27 Green Cross Corp:The インタ−フエロン−γ蛋白質の製造法
JPS63501471A (ja) * 1984-12-27 1988-06-09 サントリー株式会社 インタ−フェロンの精製方法
JPS6156195A (ja) * 1985-03-01 1986-03-20 Asahi Chem Ind Co Ltd 新規生理活性ペプチド
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
WO1986006077A1 (en) * 1985-04-08 1986-10-23 Amgen A method and a hybrid promoter for controlling exogenous gene transcription
US4873312A (en) * 1985-04-25 1989-10-10 Amgen Method for purifying interferon and composition of matter produced thereby
FR2583429B1 (fr) * 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US4845196A (en) * 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
US5104795A (en) * 1985-11-13 1992-04-14 Zoma Corporation Shortened phosphoglycerate kinase promoter
DE3687796T2 (de) * 1985-11-13 1993-06-09 Xoma Corp Verkuerzter phosphoglycerat-kinase-promotor.
EP0237019A3 (en) * 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5198343A (en) * 1986-08-05 1993-03-30 Transgene, S.A. Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained
US6238889B1 (en) * 1986-12-16 2001-05-29 Dsm N.V. Molecular cloning and expression of the Pro8 isoform of human IL-3
US4939088A (en) * 1987-02-18 1990-07-03 Meloy Laboratories Inc. Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US6384194B1 (en) * 1987-12-16 2002-05-07 Dsm N.V. Expression and purification of human interleukin-3 and muteins thereof
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
IL90021A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Process for the production of interferon
US5198212A (en) * 1988-10-31 1993-03-30 University Of Lousville Research Foundation Incorporated Method and compositions for treatment of trauma-associated sepsis with gamma interferon
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) * 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US20020168750A1 (en) * 1988-12-23 2002-11-14 James Rasmussen Enzymatically active recombinant glucocerebrosidase
US5112605A (en) * 1989-03-17 1992-05-12 Genentech, Inc. Temporal gamma-interferon administration for allergies
US5196191A (en) * 1989-03-17 1993-03-23 Genentech, Inc. Temporal gamma-interferon administration for allergies
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
ZA917669B (en) * 1990-09-27 1992-08-26 Schering Corp Antagonists of human gamma interferon
EP0487298A3 (en) * 1990-11-21 1992-12-16 Schering Corporation Human gamma interferon antagonist/agonist screen
WO1992012238A1 (en) * 1991-01-04 1992-07-23 The Board Of Regents, University Of Texas System Cloning and expression of tissue transglutaminases
US5272078A (en) * 1991-01-29 1993-12-21 Brigham And Women's Hospital CDNA encoding the type I iodothyronine 5'deiodinase
AU1337092A (en) * 1991-01-29 1992-08-27 Brigham And Women's Hospital A cdna encoding the type i iodothyronine 5' deiodinase
WO1994003599A1 (en) * 1992-08-04 1994-02-17 Sagami Chemical Research Center HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
WO1994010296A1 (en) * 1992-11-03 1994-05-11 Oklahoma Medical Research Foundation Transglutaminase gene
EP0695189B1 (en) * 1992-12-29 1998-11-25 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
EP0711829A3 (en) 1993-09-15 1997-07-09 Viagene Inc Recombinant alphavirus vector
EP0907746B1 (en) 1996-04-05 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US20020168634A1 (en) * 1999-05-05 2002-11-14 Christine Marie Debouck Methods for identifiying genes essential to the growth of an organism
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
NZ502375A (en) * 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
BR9909422A (pt) 1998-04-02 2001-09-11 Genentech Inc Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
PL356007A1 (en) 1999-11-12 2004-05-31 Maxygen Holdings Ltd Interferon gamma conjugates
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU2587002A (en) * 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
BR0206364A (pt) * 2001-01-09 2005-08-16 Baylor Res Inst Métodos para tratar doenças auto-imunes em um indivìduo e testes diagnósticos in vitro
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
CA2452119C (en) 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
JP4383534B2 (ja) * 2001-08-17 2009-12-16 コーリー ファーマシューティカル ゲーエムベーハー 改善した活性を有する組み合わせモチーフ免疫刺激オリゴヌクレオチド
IL161630A0 (en) * 2001-11-06 2004-09-27 Applied Research Systems Methods of treating endometreosis
IL161762A0 (en) * 2001-11-06 2005-11-20 Applied Research Systems Estradiol inhibiting agents in breast cancer
NZ532779A (en) * 2001-11-09 2008-04-30 Intarcia Therapeutics Inc Method for treating diseases with omega interferon
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP1497437A4 (en) 2002-05-01 2005-11-16 Cell Genesys Inc LENTIVIRAL VECTOR PARTICLES RESISTANT TO THE INACTIVATION OF A COMPLEMENT
AU2003239774A1 (en) 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
AU2003251763A1 (en) * 2002-07-03 2004-01-23 The Brighamn And Women's Hospital, Inc. Interferon gamma in the detection and treatment of angiomyolipomas
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
SG135176A1 (en) 2004-02-02 2007-09-28 Ambrx Inc Modified human four helical bundle polypeptides and their uses
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
EP1814583A2 (en) 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
ES2388068T3 (es) 2004-12-23 2012-10-08 Molmed Spa Producto de conjugación
SG173313A1 (en) 2005-01-05 2011-08-29 Biogen Idec Inc Cripto binding molecules
ATE541859T1 (de) * 2005-01-27 2012-02-15 Novimmune Sa Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送***和活塞组件
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
NZ580686A (en) * 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
US20090155838A1 (en) * 2007-11-28 2009-06-18 Smart Tube, Inc. Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
AU2010298733B2 (en) 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
DK2591006T3 (da) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
RU2446172C1 (ru) * 2011-03-24 2012-03-27 Общество С Ограниченной Ответственностью "Фармапарк" Способ получения зрелого интерферона альфа-2 человека с использованием дрожжей saccharomyces cerevisiae и штамм-продуцент интерферона альфа-2 человека (варианты)
EA023379B1 (ru) * 2011-06-21 2016-05-31 Общество С Ограниченной Ответственностью "Фарма Ген" ШТАММ ESCHERICHIA COLI BL21(DE3)-pIE-GAMMA И СПОСОБ ПОЛУЧЕНИЯ ПРЕПАРАТА НАТИВНОГО РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА ГАММА ЧЕЛОВЕКА
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
CA2860579A1 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
EP2870238A4 (en) 2012-07-05 2016-03-09 Ohio State Innovation Foundation COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
SG11201706293XA (en) 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
AU2016257023B2 (en) 2015-05-07 2022-06-30 Swedish Orphan Biovitrum Ag Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
CN108348593B (zh) 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
MX2018012376A (es) 2016-04-13 2019-08-01 Synthetic Genomics Inc Sistemas de replicón de arterivirus recombinantes y usos de estos.
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7382230B2 (ja) 2016-10-17 2023-11-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組み換えウイルスレプリコン系及びその使用
WO2018106615A2 (en) 2016-12-05 2018-06-14 Synthetic Genomics, Inc. Compositions and methods for enhancing gene expression
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
AU2018321893A1 (en) 2017-08-23 2020-03-19 Wayne State University In vivo immunoimaging of interferon-gamma
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11083786B2 (en) 2018-01-19 2021-08-10 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
BR112022018615A2 (pt) 2020-03-19 2022-12-20 Trizell Ltd Sistema de armazenamento de vírus sensível à temperatura
CN115666618A (zh) 2020-03-30 2023-01-31 崔泽尔有限公司 用于治疗癌症的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332892A (en) * 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4460685A (en) * 1980-05-29 1984-07-17 New York University Method of enhancing the production of human γ Interferon
FI64813C (fi) * 1980-12-31 1984-01-10 Ilkka Antero Palva Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer
US4376821A (en) * 1981-04-17 1983-03-15 Meloy Laboratories, Inc. Production of human IFN-gamma (immune) interferon
IL65475A0 (en) * 1981-04-17 1982-07-30 Meloy Lab Production of immune interferon and its mrna
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna

Also Published As

Publication number Publication date
EP0077670B1 (en) 1989-06-28
ATE44289T1 (de) 1989-07-15
KR840001837A (ko) 1984-06-07
EP0077670A2 (en) 1983-04-27
LU88327I2 (fr) 1994-05-04
RU2107728C1 (ru) 1998-03-27
RU2092561C1 (ru) 1997-10-10
NO164177B (no) 1990-05-28
GB2107718B (en) 1985-11-20
DE3238554C2 (it) 1989-11-23
US4727138A (en) 1988-02-23
JPS62265986A (ja) 1987-11-18
PT75696A (en) 1982-11-01
CA1341590C (en) 2009-02-03
PL153202B1 (en) 1991-03-29
DZ467A1 (fr) 2004-09-13
IL66992A0 (en) 1983-02-23
CH663619A5 (de) 1987-12-31
PL238671A1 (en) 1983-07-18
FI823528A0 (fi) 1982-10-15
JPH0135639B2 (it) 1989-07-26
HK66289A (en) 1989-08-25
NO1994025I1 (no) 1994-12-20
GB2107718A (en) 1983-05-05
BG42527A3 (en) 1987-12-15
IT1153265B (it) 1987-01-14
RU2056460C1 (ru) 1996-03-20
FI823528L (fi) 1983-04-20
DE19375065I2 (de) 2004-07-01
FI86559C (fi) 1992-09-10
FR2514783A1 (fr) 1983-04-22
SG76988G (en) 1989-03-23
DE3279788D1 (en) 1989-08-03
CZ282154B6 (cs) 1997-05-14
IL66992A (en) 1991-07-18
ES8402351A1 (es) 1984-02-01
DK460882A (da) 1983-05-27
MX166499B (es) 1993-01-12
AU561343B2 (en) 1987-05-07
NO164177C (no) 1990-09-12
DE77670T1 (de) 1987-09-03
GT198277746A (es) 1984-04-11
JPH03246232A (ja) 1991-11-01
JPH07106144B2 (ja) 1995-11-15
NO823467L (no) 1983-04-20
AU8935282A (en) 1983-04-28
DK163187C (da) 1992-06-22
US4925793A (en) 1990-05-15
RO89534A (ro) 1986-07-30
NZ202190A (en) 1987-06-30
JP2515308B2 (ja) 1996-07-10
NL930040I1 (nl) 1993-08-02
DK163187B (da) 1992-02-03
OA07233A (fr) 1984-04-30
MY102546A (en) 1992-07-31
NL930040I2 (nl) 1993-09-16
SK738982A3 (en) 1998-12-02
FR2514783B1 (fr) 1985-11-29
DE3238554A1 (de) 1983-05-05
ES516620A0 (es) 1984-02-01
ZW22282A1 (en) 1983-05-11
YU45871B (sh) 1992-09-07
IE822517L (en) 1983-04-19
PH26963A (en) 1992-12-28
CZ738982A3 (en) 1997-03-12
IE54371B1 (en) 1989-09-13
HU202287B (en) 1991-02-28
SK279535B6 (sk) 1998-12-02
YU233582A (en) 1985-03-20
FI86559B (fi) 1992-05-29
ZA827569B (en) 1983-11-30
EP0077670A3 (en) 1984-07-04
DD208822A5 (de) 1984-04-11
JPS5890514A (ja) 1983-05-30
BR8206068A (pt) 1983-09-13
BG44877A3 (it) 1989-02-15
US4762791A (en) 1988-08-09
US4929554A (en) 1990-05-29
MX9206041A (es) 1994-04-29
PT75696B (en) 1987-03-24
GR78391B (it) 1984-09-27

Similar Documents

Publication Publication Date Title
IT8223795A0 (it) Gamma), relativi veicoli di polipeptidi contenenti la sequenza espressione, loro procedimento di degli amminoacidi dell'interferone preparazione, composizioni umano immune (interferone umano farmaceutiche contenenti tali polipeptidi.
IL58759A0 (en) Purified proteins,their preparation and pharmaceutical compositions containing them
IT8467445A1 (it) Composizione e preparato per la somministrazione di medicamenti per via cutanea.
IL67572A (en) Trans-2-aza bicyclo(3.(3+n).o)alkane-3-carboxylic acid derivatives,processes for their preparation and pharmaceutical compositions containing them
NO166494C (no) Fremgangsmaate for fremstilling av human lymfoblastoid interferon.
GB2198134B (en) Substituted a-amino acids, their preparation and pharmaceutical compositions containing them
IT8224915A0 (it) Uso di peptidi come medicamenti.
IT8219947A0 (it) Complessi platino-diamminici eprocedimento per la loro preparazione nonche' formulazioni farmaceutiche antitumorali contenenti tali complessi.
IL61110A (en) Immunopotentiating thymosinlike peptides,their preparation and pharmaceutical compositions containing them
ES512087A0 (es) "procedimiento de preparacion de organopolisiloxanos de peso molecular elevado".
NO179359C (no) Fremgangsmåte for fremstilling av farmasöytisk preparat inneholdende somatostatinanaloger.
IT8421622A0 (it) Procedimento per la preparazione di peptidi.
IL72219A (en) Peptide from the calcitonin group,its production and pharmaceutical compositions containing it
DE68920896D1 (de) N2-(1-Carboxy-3-phenylpropyl)-L-lysinderivate und Verfahren für die Herstellung von Lysinopril mit Hilfe dieser Verbindung.
IL57213A (en) Substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepines,process for the preparation thereof,and pharmaceutical compositions containing them
IT8567535A1 (it) Procedimento per la preparazione di amminoidrossicefamcarbossilati.
FI854839A0 (fi) Vaccin eller diagnostisk produkt erhaollen fraon peptid, samt daeri anvaendbar polypeptid.
PT84339A (pt) 1,6-naphthyridine derivatives process for the preparation thereof and pharmaceutical compositions containing them
DE3168544D1 (en) 6,7,8,9-tetrahydro-3h-benz(e)indolamine derivatives, processes for their preparation and intermediates used therein, and pharmaceutical compositions containing the indolamine derivatives
PT74400B (en) Process for the preparation of 17,18-dehydro-apovincaminol-3', 4',5'-trimethoxy-benzoate and of pharmaceutical compositions containing them
IT8248451A0 (it) N-/-(3-amminopropil) amminobutil/2,2-diidrossietanammide come immuno stimolante ed intermedio per la produzione di sostanza carcinostatiche, e procedimento per la sua preparazione
ZA827058B (en) Derivatives of 20,21-dinoreburnamenine possibly substituted on the e ring,process for their preparation,their use as medicaments and compositions containing them and intermediates obtained
IT8322427A0 (it) Composizioni farmaceutiche adattivita'antibiotica-immunostimolante.
IT8567469A0 (it) Procedimento per la preparazionedi n benzilossicarbonil amminoacidi contenenti funzionalita addizionali
DE3275375D1 (en) Mercapto amino acids, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971030